ALNY vs. BNTX: Alnylam Pharmaceuticals vs. BioNTech Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and BioNTech (BNTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

BioNTech (BNTX) has an aggressive beta of 1.30, indicating higher sensitivity to broad-market moves, while Alnylam Pharmaceuticals (ALNY) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 52.85%, ranking against industry peers normally.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and BioNTech (BNTX) at 30.28% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while BioNTech (BNTX) at 4.32% is closer to the peer norm — faster top-line expansion for ALNY.

Neither Alnylam Pharmaceuticals (ALNY) nor BioNTech (BNTX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and BioNTech (BNTX) at 8.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and BioNTech (BNTX) at 8.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Alnylam Pharmaceuticals (ALNY) at 5.79 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics